Atossa Therapeutics FCF Margin

What does Atossa Therapeutics do? Atossa Therapeutics, Inc. generates revenue through the development of novel therapeutics for breast cancer and related conditions. Its pipeline includes Topical Endoxifen for reducing mammographic breast density and preventing gynecomastia in prostate cancer patients, alongside an oral formulation of endoxifen. The company also develops intraductal microcatheter technology for targeted delivery of therapeutics, including CAR-T therapy. These products target healthcare providers and pharmaceutical partners seeking innovative treatments for breast-related conditions. The company focuses on transdermal and oral delivery methods for endoxifen, addressing specific patient populations such as those with high mammographic breast density or undergoing androgen deprivation therapy. Its microcatheter technology enables direct therapeutic delivery to early breast cancer sites, positioning it for potential partnerships with oncology-focused institutions. The primary buyers are healthcare institutions and pharmaceutical companies interested in advancing breast cancer treatment options. Atossa's development of Topical Endoxifen for two distinct applications—reducing mammographic breast density and managing gynecomastia—creates dual revenue streams from the same therapeutic platform. The intraductal microcatheter technology represents a specialized delivery system for CAR-T therapies, attracting interest from biotechnology firms specializing in advanced cancer treatments. This strategic focus on niche delivery mechanisms differentiates the company in the oncology sector. Atossa Therapeutics is one of the most popular companies on Eulerpool.